坤泰胶囊联合低剂量米非司酮对子宫肌瘤术前治疗效果观察  

Observation on the effect of Kuntai capsule combined with low-dose mifepristone on preoperative treatment of uterine fibroids

作　　者：明小琼 Ming Xiaoqiong(CR&Wisco General Hospital,Wuhan 430080,China)

机构地区：[1]华润武钢总医院,湖北省武汉市430080

出　　处：《现代养生》2023年第11期834-837,共4页Health Protection and Promotion

摘　　要：目的 探讨坤泰胶囊联合低剂量米非司酮用于子宫肌瘤术前治疗的临床效果,并观察其对于血清转化生长因子β1(TGF-β1)和血管内皮生长因子(VEGF)的影响。方法 选取2021年1月-2022年1月就诊于医院的116例子宫肌瘤患者作为研究对象,按照组间年龄、病程、子宫肌瘤体积、肌瘤位置等基本资料均衡可比的原则分为观察组和对照组,每组58例。对照组患者采用低剂量米非司酮治疗,观察组患者采用坤泰胶囊联合低剂量米非司酮治疗,对两组患者的治疗效果进行对比和分析。结果 治疗后,观察组患者的卵泡刺激激素(FSH)、黄体生成素(LH)、雌激素(E2)、孕酮(P)、TGF-β1和VEGF水平低于对照组,差异有统计学意义(P<0.05);观察组患者的子宫体积和子宫肌瘤体积低于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应发生率低于对照组,但差异无统计学意义(P>0.05);治疗有效率高于对照组,差异有统计学意义(P<0.05)。结论 坤泰胶囊联合低剂量米非司酮在子宫肌瘤术前治疗中获得了较好的应用效果,有效降低了患者的激素水平和血清TGF-β1、VEGF表达水平,具有一定的安全性。Objective To explore the clinical effect of Kuntai capsule combined with low-dose mifepristone in the preoperative treatment of uterine fibroids and observe its effect on serum transforming growth factorβ1(TGF-βi)and vascular endothelial growth factor(VEGF).Methods A total of 116 patients with uterine fibroids who visited hospitals from January 2021 to January 2022 were selected as the research subjects.They were divided into an observation group and a control group based on the principle of balanced and comparable basic data such as age,course of disease,uterine fibroid volume,and fibroid location between groups,with 58 cases in each group.The control group patients were treated with low-dose mifepristone,while the observation group patients were treated with Kuntai capsules combined with low-dose mifepristone.The treatment effects of the two groups of patients were compared and analyzed.Results After treatment,the level of the follicle stimulating hormone(FSH),luteinizing hormone(LH),estrogen(E2),progesterone(P),TGF-βand VEGF of the observation group patients were lower than that of the control group,and the difference was statistically significant(P<0.05).The uterine volume and uterine fibroid volume of the observation group were lower than those of the control group,and the diference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,but the difference was not statistically significant(P>0.05).The effective rate of treatment was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of Kuntai capsule and low-dose mifepristone has achieved good results in the preoperative treatment of uterine fibroids,effectively reducing patients'hormone levels and serum TGF-β1 and VEGF expression level,and has a certain level of safety.

关 键 词：坤泰胶囊 米非司酮 子宫肌瘤 血清转化生长因子Β1 血管内皮生长因子 

分 类 号：R737.33[医药卫生—肿瘤]